(TEL) Picasso Worth €25m Seized From British-registered Yacht Off Corsica

Botin!!!!

Picasso Worth €25m Seized From British-registered Yacht Off Corsica
2015-08-04 12:04:09.708 GMT


Henry Samuel
Aug. 4 (Telegraph) -- French customs seize Head of Picasso's
Young Woman belonging to Spanish banking billionaire from yacht
in Corsican port of Calvi on grounds it is a Spanish "national
treasure" and not allowed out of the country.
A Pablo Picasso painting worth more than €25 million and
considered a Spanish “national treasure” has been seized from a
British-registered yacht moored off Corsica, French authorities
have confirmed.
Head of a Young Woman was seized onboard a vessel off Calvi
on the west coast of the Mediterranean island following “an
attempt to export (the work) to Switzerland”, French customs
officials confirmed in a statement.
The work Picasso painted in 1906 and valued at “more than
€25 million” is the property of Spanish billionaire Jaime Botin,
the largest shareholder of Bankinter and whose great grandfather
founded Spain’s largest bank, Santander. Mr Botin reportedly
bought the painting in 1977 at the Marlborough Fine Art Fair in
London for his personal collection.
He has a stake in the company that owns the yacht where the
painting was found but “was not on board at the time”.
The seizure is the latest chapter a three-year battle by the
79-year-old billionaire, Spain’s 15th richest man according to
Forbes, to take the Picasso out of Spain.
Mr Botin, who was Santander’s vice president from 1999 to
2004, made a formal request in 2012 via Christie’s Iberia to
definitively transfer the work from Spain to London. That request
was denied by the Spanish culture ministry on the grounds that
there was “no other similar work on Spanish soil”.
Mr Botin appealed the decision, arguing that the work was
not technically in Spain anyway as it was hanging in a yacht
called Adix moored at the Valencia Royal Nautical Club under a
British flag. He also argued he was not the direct owner, as the
work was the property of the Panamanian Society Euroshipping
Charter Company of which he is the largest shareholder.
The appeal was quashed with judges citing the 1982 Montego
Bay Convention and stating that “the existence of a ship in a
Spanish port, except in the case of military vessels, is subject
to Spanish law”.
An attempt to export the painting to Switzerland on Thursday
“drew the attention of French officials”, France’s customs
authority said, with agents boarding the boat in the port of
Calvi the following day.
The ship’s captain could only produce two documents
regarding the work of art, the statement said – one of which was
a May 2015 Spanish court ruling labelling the painting “a Spanish
national treasure (which) could under no circumstances be taken
out of Spain”.
French customs officials are now awaiting an official
Spanish request to recover the painting.

The market for Picasso paintings reached new heights in May
when Les femmes d'Alger (Version O) smashed the world record for
a painting sold at auction, fetching a fraction over $179 million
(£116m) in New York.
Brooke Lampley, the head of Impressionist and Modern Art at
Christie's, said before the auction: “There is an incredible
thirst in the market right now for top-quality works by renowned
artists. Pablo Picasso is the most highly recognised figure in
the art world today and this piece is in many ways the
culmination of his career.”
In February, a Picasso stolen from the Pompidou Centre in
Paris was found by a US customs official after it was posted
across the Atlantic disguised as a cheap Christmas present.
La Coiffeuse (The Hairdresser), painted in 1911, was
reported stolen in 2001 when it was discovered missing from the
Paris museum.
It lay hidden for the next 14 years until it turned up in
Newark in December in a FedEx package from Belgium, labelled as
“art craft/toy” with a stated value of $37 (£24) and with the
message “Joyeux Noel” (Happy Christmas).

-0- Aug/04/2015 12:04 GMT

>>> Shire goes public with a $30B bid to acquire Baxalta, expand rare-disease pi

Shire goes public with a $30B bid to acquire Baxalta, expand rare-disease pipeline

After getting stiff armed by the newly independent management at Baxter's biotech spinoff Baxalta, Shire is going public with its offer to acquire the company for $30.6 billion in shares. The deal marks Shire CEO Flemming Ornskov's play to make a landmark acquisition that can vault the company into the big leagues, after being left at the altar last year by AbbVie.

Coming in at a value of $45.23 a share, the deal now on the table marks a 36% increase over Baxalta's Monday share price close. Ornskov tried to start M&A talks just days after Baxalta completed its spinout July 1. But Shire also disclosed that Baxalta's CEO quickly rejected the offer and has shown little interest in resuming talks. Shire styled the all-stock offer as a strategy that would allow Baxalta's shareholders to retain the tax-free structure of their spinoff from Baxter.

If Baxalta changes its minds – which will require a bigger number than what's on the table now – Ornskov is promising to create a company with $20 billion in sales by 2020. Such an acquisition would create "the leading global biotech company in rare diseases," Ornskov noted.
"It is our strong preference to immediately enter into a negotiated transaction to explore the full potential of the proposed combination and finalize the terms of an agreement," Ornskov said in a statement. By making the terms public, Shire is hoping that Baxalta's shareholders will rally around the deal.

Shire, which is likely to reignite the debate over biotech valuations, saw its share price drop 4% after the news hit. Baxalta's shares jumped more than 20%.

"We have sought to engage with you regarding such a combination since early July," Ornskov wrote in a letter to Baxalta CEO Lutwig Hantson. "Other than a brief meeting on July 10th at which we outlined our proposal and its benefits, your lack of engagement has been surprising. On July 31st, weeks after receiving our written proposal and without any meaningful interaction, you stated that you had concluded it was not a basis for discussions. As a result, you have left us with no choice but to make our proposal known to your shareholders. We believe they deserve an opportunity to consider it."

It's been clear for months now that Shire has been focused on completing a major M&A deal that could significantly boost the value of the company. AbbVie decided to walk away from their deal to buy Shire last year after the federal government changed the tax rules that once made a Shire acquisition an appealing prospect for any big player that wanted to trade their relatively high U.S. rate for Shire's U.K. tax tab.

Up to now, Ornskov has been primarily interested in snapping up relatively small bolt-on deals, like yesterday's $300 million buyout of Foresight Biotherapeutics, adding a Phase III-ready eye drug to the pipeline. Baxalta is another story altogether.

Baxalta is built on a foundation of hemophilia drugs now on the market. But it's been hustling along next-gen therapies in the field aimed at keeping with a competitive group of rivals in the field. Their late-stage assets include BAX 855, a long-acting hemophila A therapy now under FDA review. BAX 111 has been submitted for rare cases of von Willebrand disease. There have been licensing deals for Merrimack's pancreatic cancer treatment MM-398, CTI BioPharma's myelofibrosis drug pacritinib and Onconova's rigosertib, all in late-stage development. And Baxalta's $225 million deal to buy SuppreMol added a mid-stage drug fpr lupus and idiopathic thrombocytopenic purpura.

Shire, meanwhile, has been working at building a pipeline of new opthalmology drugs while building on its foundation of rare disease treatments. Gaining control of Baxalta's pipeline would satisfy Ornskov's desire for rapid growth in the field.

(BFW) MORE: Shire Says Baxalta Declined to Engage in Substantive Talks


BN 08/04 11:39 Shire Makes Unsolicited Bid to Acquire Baxalta for $30 Billion
BFW 08/04 11:34 Shire Proposes Baxalta Combination; Implied Value $45.23/Shr
PRN 08/04 11:30 Shire Proposes Combination With Baxalta to Create the Leading Global Biotech Company Focused on Rare Diseases
BN 08/04 11:34 *SHIRE WOULD SEE $20B COMBINED PRODUCT SALES BY 2020 POST MERGER
BN 08/04 11:34 *SHIRE SAYS HASN'T DISCUSSED THIS PROPOSAL WITH BAXTER
BN 08/04 11:34 *SHIRE: TAX-FREE MOVE OF BAXALTA/BAXTER SPLIT WON'T BE AFFECTED
BN 08/04 11:33 *SHIRE SEES DEAL ADDING AFTER YR 1, SUPPORTED BY A SHARE BUYBACK
BN 08/04 11:32 *SHIRE PLANS BUY BACK UP TO 13% COMBINED POST DEAL SHRS W/ DEAL
BN 08/04 11:32 *SHIRE SEES DEAL ACCRETIVE ADJ. EARNINGS; BREAKEVEN IN YEAR ONE
BN 08/04 11:32 *SHIRE URGES BAXALTA TO ENGAGE IN A NEGOTIATED TRANSACTION
BN 08/04 11:32 *SHIRE PROPOSAL STRUCTURED AS ALL-STOCK DEAL
BN 08/04 11:32 *BAXALTA HOLDERS WOULD OWN ABOUT 37% OF COMBINED SHIRE GROUP
BN 08/04 11:32 *SHIRE SAYS BAXALTA HAS DECLINED TO ENGAGE IN TALKS
BN 08/04 11:31 *SHIRE WOULD INITIATE BUYBACK UP TO 13% COMBINED POST-DEAL SHRS
BN 08/04 11:31 *BAXALTA HAS DECLINED TO ENGAGE IN SUBSTANTIVE TALKS
BN 08/04 11:31 *SHIRE OFFERS TO BUY BAXALTA FOR ABOUT $45.23 PER SHR
BN 08/04 11:31 *SHIRE: PROPOSAL REFLECTS PREMIUM 36% VS BAXALTA'S AUG. 3 PRICE
BN 08/04 11:31 *SHIRE: OFFERS FOR EACH BAXALTA SHR 0.1687 SHIRE ADS
BN 08/04 11:31 *SHIRE MAKES PROPOSAL TO BAXALTA FOR IMPLIED VALUE $45.23/SHR
BN 08/04 11:30 *SHIRE COMBINATION OFFERS OPERATING SYNERGY POTENTIAL
BN 08/04 11:30 *SHIRE ALL-STOCK TRANSACTION OF ABOUT $30B
BN 08/04 11:30 *SHIRE PROPOSES COMBINATION W/ BAXALTA TO CREATE LEADING GLOBAL

MORE: Shire Says Baxalta Declined to Engage in Substantive Talks
2015-08-04 11:39:23.801 GMT


By Gaurav Panchal
(Bloomberg) -- Says Baxalta has declined to engage in
substantive discussions regarding the proposal of 0.1687 Shire
ADRs per share leading to an all-stock deal of ~$30b.

* Says transaction is expected to generate double-digit top-
line growth; strong returns and attractive value creation;
breakeven to Non GAAP EPS in year one with accretion
thereafter
* Baxalta and Shire are projected to deliver product sales
of $20b in 2020
* Says deal offers significant operating synergy potential and
a compelling tax profile (projected 16%-17% combined non
GAAP effective tax rate by 2017), IRR in excess of 10%
* Buyback:
* Promptly after deal close, Shire would start buy-back
program to repurchase, within two years, up to 13% of
combined post-transaction shares out
* This will enhance earnings accretion of the
transaction while maintaining financial flexibility
and an investment-grade credit profile
* Proposed deal structured as an all-stock transaction to
maintain tax-free nature of Baxalta’s July 1, spinoff from
Baxter
* Baxalta shareholders would own approximately 37% of the
combined Shire group
* Baxalta rises 30% in pre-market trading
* Statement:Link


Link to Company News:{BXLT US <Equity> CN <GO>}
Link to Company News:{SHP LN <Equity> CN <GO>}

For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}

To contact the reporter on this story:
Gaurav Panchal in London at +44-20-3525-0511 or
gpanchal2@bloomberg.net

To contact the editor responsible for this story:
Tim Barwell at +44-20-3525-3512 or
tbarwell@bloomberg.net

>>> DJ Newly Born Baxalta Gets $30B Approach From Shire -- Market Talk

DJ Newly Born Baxalta Gets $30B Approach From Shire -- Market Talk
7:54 EDT - Baxalta (BXLT) has only been public 5 weeks and the drug maker has already gotten a suitor as Shire (SHPG) makes public a $30B all-stock acquisition which values the Baxter (BAX) spinoff at a 36% premium to yesterday's close. It's the latest offer in what's been a wild-and-crazy 2015 from drug M&A, which followed a quite-busy 2014. SHPG says the combined company would have multiple billion-dollar sellers in the rare-disease space. No surprise that BXLT has for now put off the approach--as has repeatedly occured as desired drug makers have played hard to get amid an effort to boost the takeout price. And that strategy has proved successful time and again. BLXT is up 24% premarket at $41 while SHPG falls some 5.5% in London.

>>> US Early premarket gappers

Early premarket gappers
Gapping up: LONG +19.5%, MDAS +12.5%, PLOW +10.8%, IDTI +9.6%, ALLT +9.5%, ININ +8.9%, TREE +8.4%, CYH +7.1%, FIVN +6.7%, BPI +6.6%, REGN +5.5%, DPLO +5.3%, CTRP +5.3%, LMNX +4.3%, CRTO +3.3%, ABMD +2.5%, NGLS +2.4%, EMR +2.3%, COH +2.2%, RSPP +1.9%, SYKE +1.8%, QLYS +1.7%, ODP +1.3%, CVS +1.1%, THC +1%

Gapping down: TNET -26.4%, CGNX -19.9%, KLIC -7.8%, VNR -7.1%, CHGG -7%, PLUG -5.3%, DENN -4.8%, ALL -4.6%, TXRH -4.4%, RRD -4.1%, IMPR -3.9%, SGMS -3.7%, SCOR -3.6%, EIGI -2.9%, EIGI -2.9%, ONDK -2.8%, RRTS -2.6%, IART -2.5%, MCHP -2.3%, CPF -1.4%, BNFT -1.2%, ELGX -1.2%, BMRN -1.1%, ALR -0.8%, NAO -0.7%, GLRE -0.6%, WLKP -0.6%